Blog Posts in April, 2005

  • A Closer Look at The Suicide Risk With Epilepsy Drugs

    On April 20, 2005, the FDA declared that manufactures of epilepsy drugs, such as Neurontin and Depakote, need to reexamine their data to see if there is a link between the drugs use and increase in suicide and suicidal behavior. This is similar to last year’s request by the FDA regarding the suicide rate in children and antidepressants known as SSRI’s. The FDA placed its sternest warning, the ...
    Continue Reading
  • Well, when you put it that way....

    It is true that statistics can be used to reach almost any desired effect depending on the context of their use. Conceding this fact, the following numbers taken from a brief article in the April, 2005, edition of Popular Science is numbing: 100 Percent increase in risk of heart attack and stroke found in a 2004 Merck-sponsored study of 2,586 patients taking the painkiller Vioxx (MD Anderson ...
    Continue Reading
  • Vioxx, Celebrex and Bextra Come Together in Federal Court

    The more lawsuits that are filed on behalf of those injured by Bextra and Celebrex, the more consolidation seems appropriate. A handful of attorneys in Louisiana are asking the JPML to place Bextra and Celebrex cases in with the Vioxx MDL. Learn about MDL’s here . This makes sense considering that the drugs work the same way on the body, cause the same types of cardiovascular events, and present ...
    Continue Reading
  • FDA Warnings: All Show No Substance

    On April 7, 2005, the FDA required Pfizer to put a “black box” warning on Celebrex labels. This is the strongest warning available to the FDA, and requires doctors to prescribe Celebrex as a last resort for patients suffering from pain. The drug is also contraindicated for those post-coronary artery bypass surgery. This all sounds good, but the fact is that many doctors and patients will never ...
    Continue Reading
  • Vioxx Recalled for Suspected Link to Heart Conditions

    On September 30, 2004, Merck Pharmaceuticals voluntarily withdrew the drug Vioxx from the market. The withdrawal came at the conclusion of a long clinical study to test the effectiveness of the drug on the reduction of colon polyps. During that study, it became clear that people on the drug for more than eighteen months were at twice the risk for heart attacks, strokes, and other serious ...
    Continue Reading
  • What in the H*** is a MDL?

    The withdrawal of Vioxx, and more recently Bextra, has created a hum of corporate irresponsibility and deception. Hundreds of Vioxx and an increasing number of Bextra lawsuits are filed . As these cases progress, you will here more and more on the topic of Multi District Litigation, or a “MDL.” Below is some helpful information on an MDL and its procedural workings. An MDL is an attempt to ...
    Continue Reading
  • Celebrex Receives Black Box Warning

    Blackbox Warnings Added to Celebrex Label On April 7, 2005, the FDA forced Pfizer to add its sternest warning for a medication. The "black box" warnings alert consumers of the serious cardiovascular risks such as heart attacks and strokes. Studies as far back as 1999 and as recent as December of 2004 link Celebrex with an increased risk of cardiovascular events. The FDA considered the findings of ...
    Continue Reading
  • Cox-2 Inhibitors Linked to Cardiovascular Issues

    You have probably seen or read about Cox inhibitors in the news recently. All Cox inhibitors are part of a class of drugs called non-steroidal anti-inflammatory drugs (NSAID). While successful for millions of Americans in reducing pain, certain NSAIDs have long been associated with serious cardiovascular problems. NSAIDs work by inhibiting proteins called cyclo-oxygenase 1 and 2 (Cox 1 & Cox 2). ...
    Continue Reading
Page 1 of 1
Free Consultation
  • Please enter your first name.
  • Please enter your last name.
  • Please enter your email.
    This isn't a valid email address.
  • Please enter your phone number.
    This isn't a valid phone number.
  • Please make a selection.
  • Please make a selection.
  • Please make a selection.
  • Please make a selection.
  • Please enter your message.